8月13日，浩欧博今日收盘116.9元，上涨2.26%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到214.27倍，总市值74.21亿元。 江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是 过敏试剂产品、自免试剂产品、仪器。截至报告期末，公司已获226项产品注册证书，57项专利。公司 为高新技术企业，曾先后被评为"江苏省免疫诊断工程技术研究中心"、"江苏省过敏原诊断工程技术研 究中心"、"省级工业企业技术中心"，荣获苏州市"创新先锋企业"、"瞪羚企业"、"五星级信用企 业"、"企业信用评价3A级信用企业"、"科技企业上市奖""安全生产月优秀组织奖"、"2021年江苏医学科 技奖二等奖"及"苏州市生物医药产业潜力地标企业"、"江苏省专精特新中小企业""安全生产党员先锋 岗"、"医疗器械产业专项奖""苏州市总部企业"、"国家级专精特新'小巨人'企业"等荣誉称号。 最新一期业绩显示，2025年一季报，公司实现营业收入7761.28万元，同比-9.33%；净利润163.92万元， 同比-56.97%，销售毛利率57.98%。 序号股票简称PE(TTM)PE(静 ...

Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy reagents and autoimmune reagents [2] - The company has obtained 226 product registration certificates and holds 57 patents, recognized as a high-tech enterprise [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% [2] - The gross profit margin stands at 57.98% [2] Market Position - As of August 5, the company's stock closed at 118.7 yuan, with a rolling PE ratio of 217.57 times, significantly higher than the industry average of 54.24 times and the median of 37.92 times [1][3] - The total market capitalization is 7.535 billion yuan [1] Institutional Holdings - By the end of Q1 2025, 12 institutions held shares in Haobio, with a total of 1.1392 million shares valued at 155 million yuan [1]

截至2025年一季报，共有12家机构持仓浩欧博，其中基金12家，合计持股数113.92万股，持股市值1.55 亿元。 7月30日，浩欧博今日收盘120.91元，下跌3.13%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到221.62倍，总市值76.75亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，浩欧博排名 第114位。 最新一期业绩显示，2025年一季报，公司实现营业收入7761.28万元，同比-9.33%；净利润163.92万元， 同比-56.97%，销售毛利率57.98%。 江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是 过敏试剂产品、自免试剂产品、仪器。截至报告期末，公司已获226项产品注册证书，57项专利。公司 为高新技术企业，曾先后被评为"江苏省免疫诊断工程技术研究中心"、"江苏省过敏原诊断工程技术研 究中心"、"省级工业企业技术中心"，荣获苏州市"创新先锋企业"、"瞪羚企业"、"五星级信用企 业"、"企业信用评价3A级信用企业"、"科技企业上市奖""安全生产月优秀组织奖"、"2021年 ...

7月29日，浩欧博今日收盘124.82元，上涨2.86%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到228.78倍，总市值79.24亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13浩欧博228.78215.299.7279.24亿行业平均 55.4650.344.76115.47亿行业中值37.7437.642.7056.85亿1九安医疗10.9411.070.86184.69亿2英科医疗 13.3414.381.19210.74亿3新华医疗15.3914.261.2598.65亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2816.331.87154.02亿6奥美医疗16.3015.971.6858.89亿7康德莱17.0517.061.4136.73亿8九强生物 17.6216.382.1687.24亿9奥泰生物18.0719.051.4657.63亿10维力医疗18.5919.332.1842.41亿11三鑫医疗 20.0220.033.2945.55亿12鱼跃医疗20.0519.662.71355.08亿 来源：金融界 江苏浩欧博生物医药股份 ...

Group 1 - The core business of the company is the research, production, and sales of in vitro diagnostic reagents, with major products including allergy reagents and autoimmune reagents [2] - As of the latest report, the company has obtained 226 product registration certificates and holds 57 patents, indicating a strong position in innovation and technology [2] - The company has received multiple honors, including being recognized as a high-tech enterprise and receiving various awards for innovation and creditworthiness [2] Group 2 - As of June 3, the company's stock closed at 93.24 yuan, down 2.70%, with a rolling PE ratio of 169.77 times, significantly higher than the industry average of 50.80 times [1][3] - The total market capitalization of the company is 5.88 billion yuan, ranking 113th in the industry based on PE ratio [1][3] - The latest quarterly report for Q1 2025 shows a revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% year-on-year, with a gross margin of 57.98% [2]

Company Overview - Jiangsu Haooubo Biomedicine Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy reagents and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, and is recognized as a high-tech enterprise with multiple awards for innovation and creditworthiness [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% year-on-year, with a gross margin of 57.98% [2] Market Position - As of May 29, the company's stock closed at 89.1 yuan, with a rolling price-to-earnings (PE) ratio of 162.23, significantly higher than the industry average PE of 49.64 and median PE of 36.36, placing the company at rank 114 in the industry [1][3] - The total market capitalization of the company is 5.618 billion yuan [1] Shareholder Information - As of March 31, 2025, the company had 3,065 shareholders, an increase of 30 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Core Viewpoint - Jiangsu Haobio's stock closed at 86.8 yuan, down 4.67%, with a rolling PE ratio of 158.04 times, significantly higher than the industry average of 49.84 times [1][3] Company Overview - Jiangsu Haobio Biopharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, recognized as a high-tech enterprise and awarded multiple honors, including "Innovative Pioneer Enterprise" and "National Specialized and New 'Little Giant' Enterprise" [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97%, with a gross margin of 57.98% [2] Market Position - As of Q1 2025, 11 institutions held shares in Haobio, with a total of 46.12 million shares valued at 4.007 billion yuan [1]